According to Thomas Jefferson University researchers, adding B cell activating factor (BAFF) to a rabies vaccine can boost its efficacy. Results of their research were published in PLOS Neglected Tropical Diseases today.

Previous studies have suggested that the existing rabies vaccine, which is costly and complicated to administer, works by activating the immune system's B cells. However it can take time for the vaccine, which contains inactivated virus particles, to interact with the B cells.

In the new study, James McGettigan and colleagues used BAFF, a signaling protein that binds directly to B cells. They designed a rabies vaccine that included an attenuated rabies virus and BAFF on the same particle, hoping to target the vaccine directly to B cells for activation.

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

Mice immunized with the new BAFF-enhanced rabies vaccine showed a faster and stronger response of the immune system compared to animals that received the typical vaccine. Levels of virus neutralizing antibodies increased more quickly and to higher levels, however the duration of the response was not affected.

"This new vaccine strategy significantly enhanced the speed and magnitude of the anti-rabies antibody responses and has the potential to improve the efficacy of currently used inactivated RABV-based vaccines," the researchers say.